Abstracts tagged "autoimmune diseases"

Abstract Number: PP15 • ACR Convergence 2024
Breathing Mindfully and How to Control Anxiety in Lupus Patients
Amanda Greene, Lupus Research Alliance, Los Angeles, CA
Background/Purpose: For over four decades, Systemic Lupus Erythematosus has impacted my Quality of Life.. I was diagnosed in 1983- my entire life was changed. I…
Abstract Number: 0014 • ACR Convergence 2024
Phenotypic Validation of Humanized IgA1 and CD89 Transgenic Mice as a Model for IgA Nephropathy-Like Autoimmune Disease
Kaiyuan Zi and Juan Liang, GemPharmatech, San Diego
Background/Purpose: The etiology of IgA nephropathy (IgAN) remains only partly understood, but the presence of IgA antibodies together with the myeloid IgA-receptor FcαRI/CD89 complexes in…
Abstract Number: 0138 • ACR Convergence 2024
SARS-CoV-2 Vaccine Acceptance, Hesitancy and Uptake in a Cohort of Patients with Inflammatory Rheumatic Diseases (IRD)
iulia roman¹, Xenofon Baraliakos², Uta Kiltz³, Juergen Braun⁴ and Ioana Andreica⁵, ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ³Rheumazentrum Ruhrgebiet Herne, Ruhr-University, D-44649 Herne, Germany, ⁴Rheuma Praxis, Ruhr-University Bochum, Berlin, Germany, ⁵Rheumazentrum Ruhrgebiet Herne, Herne, Germany
Background/Purpose: Vaccine acceptance is important to achieve high vaccination coverage and possibly herd immunity. Related to the evolution of the SARS-CoV-2 pandemic with its socio-political…
Abstract Number: 0288 • ACR Convergence 2024
Hypersensitivity Pneumonitis with Autoimmune Features: A New Entity?
Pol Maymó¹, Javier Narvaez-García², Guadalupe Bermudo¹, Vanesa Vicens-Zygmunt³, Santiago Bolivar⁴, Belen del Río⁵, Judith Palacios⁵, Martí Aguilar Coll², Monserrat Roig Kim², Laia De Daniel², Paola Vidal¹, Joan Miquel Nolla² and María Molina¹, ¹Hospital Universtiario de Bellvitge, Barcelona, Spain, ²Hospital Universitario de Bellvitge, Barcelona, Spain, ³Hospital Universitario de Bellvitge., Barcelona, Spain, ⁴Bellvitge University Hospital, L'Hospitalet de Llobregat, Catalonia, Spain, ⁵Hospital Universtiario de Bellvitge, Hosptalet de Llobregat, Catalonia, Spain
Background/Purpose: Hypersensitivity pneumonitis (HP) is an interstitial lung disease induced by inhaled antigens that trigger an interstitial and bronchoalveolar lymphocytic inflammatory response. This immune response…
Abstract Number: 0366 • ACR Convergence 2024
Factors Associated with Participation in Rheumatology Clinical Trials: A UK-based Study
Koushan Kouranloo¹ and Chris Wincup², ¹Internal Medicine Resident., London, United Kingdom, ²King's College Hospital, London, United Kingdom
Background/Purpose: Clinicians are encouraged to consider patient preferences for offering face-to-face vs virtual consultations. This adaptability is particularly important to rheumatologists caring for patients with…
Abstract Number: 0570 • ACR Convergence 2024
Prevalence of Comorbidities and Racial Disparities in Anterior Uveitis Risk Among Ankylosing Spondylitis Patients
Halah Alfatlawi¹, abdulmajeed alharbi², eun seo kwak², rawnag el sheikh² and nezam altorok², ¹the university of toledo, Toledo, OH, ²the university of toledo, Toledo
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory condition primarily affecting the axial spine, commonly associated with extra-articular manifestations such as anterior uveitis (AU). Racial…
Abstract Number: 0778 • ACR Convergence 2024
Comprehensive Immune Profiling of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Patients with Autoimmune Disease
Justin Chou¹, Ricardo Grieshaber-Bouyer², Michelle J Wu³, Christina Bergmann², Jule Taubmann⁴, Fabian Müller⁵, Aline Bozec⁴, Tobias Rothe², Andreas MAckensen⁶, Amber Podoll⁷, Jonathan Gutman⁷, Aiden Haghikia⁸, Dimitrios Mougiakakos⁹, Gary Tong³, Pouya Kheradpour³, Francis Kim¹⁰, Prameela Ramesan¹⁰, Brandon Kwong¹⁰, Kunbin Qu¹⁰, Bishwa Ganguly¹⁰, Dominic Borie¹⁰, James Chung¹⁰ and Georg Schett¹¹, ¹Kyverna Therapeutics, Emeryville, CA, ²Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ³Verily Life Sciences, South San Francisco, CA, ⁴Friedrich-Alexander Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁵Department of Medicine 5 - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Uniklinikum Erlangen, Erlangen, Germany, ⁶Department of Medicine 5 - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Uniklinikum Erlangen, Erlangen, Bayern, Germany, ⁷University of Colorado Anschutz Medical Campus, Aurora, CO, ⁸Otto-von-Guericke University, Magdeburg, Germany, ⁹Otto-von-Guericke University, Magdeburg, Germany, Magdeburg, Germany, ¹⁰Kyverna Therapeutics, Inc., Emeryville, CA, ¹¹Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
Background/Purpose: Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy represents a promising advancement in the treatment of autoimmune diseases, including systemic sclerosis (SSc), idiopathic inflammatory myopathy…
Abstract Number: 0889 • ACR Convergence 2024
Unraveling the Progression of Sjögren’s Disease at the Cellular and Histological Level Using Single-cell and Spatial Transcriptomics
Tomás Gomes¹, Matilde Bandeira², Rui do Amaral Vieira¹, Bianca Correia¹, Sofia Barreira³, Pedro Gaspar⁴, Rita Cruz-Machado⁵, Beatriz Filipe¹, Pedro Ávila-Ribeiro¹, Filipa Ribeiro¹, Bruno Vidal¹, Beatriz Val¹, Filipa Costa⁶, Ana Teodósio Chícharo⁷, Augusto Silva¹, Manuel Silvério-Antonio¹, João Forjaz Lacerda¹, João Eurico Fonseca¹, Dolores López Presa⁸, Nikita Khmelinskii¹, Saumya Kumar⁹, Luis Graca¹ and Vasco C. Romão¹⁰, ¹Instituto de Medicina Molecular (iMM Lisboa), Lisboa, Portugal, ²Centro Hospitalar Universitario Lisboa Norte, Lisboa, Portugal, ³Unidade Local de Saúde Santa Maria, Serviço de Reumatologia e Doenças Ósseas Metabólicas, Lisboa, Portugal, Lisbon, Portugal, ⁴Internal Medicine Department, Hospital Santa Maria, Unidade Local de Saúde Santa Maria, Lisbon, Portugal, Povoa de Santa Iria, Portugal, ⁵Unidade Local de Saúde Santa Maria, Serviço de Reumatologia e Doenças Ósseas Metabólicas, Lisboa, Portugal, Lisboa, Portugal, ⁶Rheumatology Department, Unidade Local de Saúde de Santa Maria. Rheumatology Research Unit, Instituto de Medicina Molecular João Lobo Antunes, Lisbon, Portugal, ⁷Unidade Local de Saúde do Algarve, Hospital de Faro, Faro, Portugal, Faro, Portugal, ⁸Pathology Department, Unidade Local de Saúde de Santa Maria, Lisbon Academic Medical Centre, Lisboa, Portugal, ⁹TWINCORE, a joint venture between the Helmholtz-Centre for Infection Research (HZI) and the Hannover Medical School (MHH), Hannover, Germany, Hannover, Germany, ¹⁰Rheumatology Department, ULS Santa Maria & Rheumatology Research Unit, Instituto Medicina Molecular, Faculty of Medicine, University of Lisbon, Lisbon, Portugal
Background/Purpose: Sjögren’s Disease (SjD) is a systemic autoimmune disease that primarily targets salivary and lacrimal glands, causing tissue deterioration and loss of function. Disease progression…
Abstract Number: 0967 • ACR Convergence 2024
Transcriptional Heterogeneity of Immune Cells in the Esophagus of Systemic Sclerosis Patients: A Comparison of Upper and Lower Esophageal Regions
Hadijat Makinde¹, Miranda Gurra¹, Salina Dominguez², Matthew Dapas², Tyler Therron², Kathleen Aren³, Marie-Pier Tetreault², Monique Hinchcliff⁴, Deborah Winter⁵ and Harris Perlman¹, ¹Northwestern University, Chicago, IL, ²Northwestern University, Chicago, ³Northwestern University Division of Rheumatology, Chicago, IL, ⁴Yale School of Medicine, Westport, CT, ⁵Northwestern University, Skokie, IL
Background/Purpose: Systemic sclerosis (SSc) is characterized by an initial inflammatory phase followed by fibrosis. Esophageal dysfunction in SSc is associated with gastroesophageal reflux, leading to…
Abstract Number: 1121 • ACR Convergence 2024
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of AMG 329, a Monoclonal Antibody, in Conventional and Plasmacytoid Dendritic Cell-Mediated Rheumatic Diseases
Alan Kivitz¹, Stanley Cohen², Annie Lau-Kilby³, Yajing Sun³, Jiayin Huang³, Atasi Jana³, Susie Kim³, Yanping Wu³, Quinnie Yang³ and Lin Zhao³, ¹Altoona Center for Clinical Research, Duncansville, PA, ²Metroplex Clinical Research Center, dallas, TX, ³Amgen Inc., Thousand Oaks, CA
Background/Purpose: AMG 329 (formerly HZN-1116), a human monoclonal antibody (mAb), binds to soluble and membrane-bound human feline McDonough sarcoma (FMS)-like tyrosine kinase 3 receptor ligand…
Abstract Number: 1406 • ACR Convergence 2024
Development and Functional Characterization of Salivary Gland Organoids to Investigate Sjögren’s Disease
Negaar Goudarzi¹, Loïc Meudec², Juliette Pascaud², Fanny Jaulin³, Quentin Pascal⁴, Thierry Lazure⁵, Sacha E Silva Saffar², Xavier Mariette⁶ and Gaetane Nocturne⁶, ¹University Paris-Saclay, Le Kremlin Bicêtre, France, ²University Paris Saclay, Le Kremlin Bicetre, France, ³Institut Gustave Roussy, Villejuif, France, ⁴CEA, Fontenay aux roses, France, ⁵APHP. Université Paris-Saclay, Hôpital Bicêtre, Anatomie et cytologie pathologiques, Paris, France, ⁶Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France
Background/Purpose: Sjögren’s disease (SjD) is a systemic autoimmune disease that manifests as glandular dryness and systemic symptoms. Salivary gland epithelial cells (SGEC) are pivotal in…
Abstract Number: 1555 • ACR Convergence 2024
Sustained Functional Assessment of Chronic Illness Therapy–Fatigue Response in Patients with SLE Receiving Anifrolumab Alongside Standard Therapy
Vibeke Strand¹, Kenneth Kalunian², Ian Bruce³, Caroline Seo⁴, Kai Wai Lee⁵, Jacob Knagenhjelm⁶ and Catharina Lindholm⁶, ¹Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ²University of California San Diego, La Jolla, CA, ³Centre for Musculoskeletal Research, The University of Manchester, Manchester, United Kingdom, ⁴BioPharmaceuticals Medical Evidence, AstraZeneca, Gaithersburg, MD, ⁵Biopharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ⁶BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden
Background/Purpose: Fatigue is highly prevalent and severely affects health-related quality of life (HRQoL) in patients with SLE.1,2 We previously demonstrated that, compared with placebo, a…
Abstract Number: 1688 • ACR Convergence 2024
Discovery and Validation of a New Classification of ANA-RMDs That Better Predict Long Term Outcomes Compared to Legacy Diagnoses
Jack Arnold¹, Lucy Carter¹, Yuzaiful Yusof², Zoe Wigston², Daniel Toro Dominguez³, Samuel Relton⁴, Guillermo Barturen⁵, Marta Alarcon-Riquelme⁶ and Edward Vital⁷, and PRECISESADS consortium, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK, Leeds, United Kingdom, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK, Leeds, England, United Kingdom, ³Centro Pfizer-Universidad de Granada-Junta de Andalucía de Genómica e Investigación Oncológica (GENYO), Granada, Andalucia, Spain, ⁴Leeds Institute of Data Analytics, University of Leeds, Leeds, UK, Leeds, England, United Kingdom, ⁵Center for Genomics and Oncological Research (GENYO), Andalusia, Spain, ⁶Fundación Progreso y Salud, Andalusian Government, Granada, Spain, ⁷Leeds Institute of Rheumatic and Musculoskeletal Medicine, Faculty of Medicine and Health, University of Leeds, Leeds, United Kingdom, Leeds, England, United Kingdom
Background/Purpose: ANA-associated RMDs (ANA-RMDs) include SLE, Sjogren’s, Scleroderma, Myositis, and mixed/undifferentiated CTD. Despite overlapping clinical and immunophenotypic features, there is significant disparity in access to…
Abstract Number: 1807 • ACR Convergence 2024
Identification of HDAC Inhibitor Targeting Type I Interferon and B-cell Abnormalities in Systemic Lupus Erythematosus
Takehiro Hirayama¹, Hyota Takamatsu² and Atsushi Kumanogoh³, ¹Osaka university, ibaraki city, Japan, ²National Hospital Organization Osaka Minami Medical Center, kawachinagano, Japan, ³Osaka University, Osaka, Japan
Background/Purpose: This study aimed to identify drugs that can inhibit both type I interferon (IFN-I) production and abnormal B-cell maturation and to elucidate the therapeutic…
Abstract Number: 1879 • ACR Convergence 2024
Prevalence of Relapsing Polychondritis in Colombia: Data from the National Health Registry 2018 – 2023
Mario Bautista-Vargas¹, Adrian Romero-Ocampo², Juan José Pino Vélez³, juliana Muñoz-Bedoya⁴ and Diego Rosselli⁵, ¹Mayo Clinic, Rochester, Minnesota, USA., Rochester, MN, ²Universidad de Antioquia, Medellín – Colombia, Medellin, Antioquia, Colombia, ³Universidad de Antioquia, Envigado, Antioquia, Colombia, ⁴Universidad Corpas, Bogotá, Colombia, ⁵Pontificia Universidad Javeriana, Bogotá, Colombia
Background/Purpose: The implementation of the SISPRO system enables it to function as a tool capable of collecting pertinent health system data. This information is publicly…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].